全文获取类型
收费全文 | 31575篇 |
免费 | 4699篇 |
国内免费 | 86篇 |
专业分类
耳鼻咽喉 | 374篇 |
儿科学 | 791篇 |
妇产科学 | 936篇 |
基础医学 | 3204篇 |
口腔科学 | 565篇 |
临床医学 | 7534篇 |
内科学 | 5240篇 |
皮肤病学 | 534篇 |
神经病学 | 3408篇 |
特种医学 | 686篇 |
外科学 | 3852篇 |
综合类 | 399篇 |
一般理论 | 31篇 |
预防医学 | 4185篇 |
眼科学 | 672篇 |
药学 | 1795篇 |
中国医学 | 19篇 |
肿瘤学 | 2135篇 |
出版年
2024年 | 104篇 |
2023年 | 663篇 |
2022年 | 385篇 |
2021年 | 809篇 |
2020年 | 739篇 |
2019年 | 729篇 |
2018年 | 1358篇 |
2017年 | 1248篇 |
2016年 | 1213篇 |
2015年 | 1291篇 |
2014年 | 1603篇 |
2013年 | 1954篇 |
2012年 | 1949篇 |
2011年 | 2037篇 |
2010年 | 1419篇 |
2009年 | 1468篇 |
2008年 | 1594篇 |
2007年 | 1554篇 |
2006年 | 1606篇 |
2005年 | 1564篇 |
2004年 | 1239篇 |
2003年 | 1110篇 |
2002年 | 1032篇 |
2001年 | 530篇 |
2000年 | 394篇 |
1999年 | 494篇 |
1998年 | 525篇 |
1997年 | 483篇 |
1996年 | 545篇 |
1995年 | 438篇 |
1994年 | 400篇 |
1993年 | 313篇 |
1992年 | 335篇 |
1991年 | 300篇 |
1990年 | 276篇 |
1989年 | 246篇 |
1988年 | 196篇 |
1987年 | 188篇 |
1986年 | 176篇 |
1985年 | 148篇 |
1984年 | 124篇 |
1983年 | 113篇 |
1982年 | 110篇 |
1981年 | 86篇 |
1980年 | 89篇 |
1979年 | 113篇 |
1978年 | 100篇 |
1977年 | 91篇 |
1974年 | 83篇 |
1971年 | 84篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
992.
993.
994.
995.
Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA‐NCI roundtable symposium 下载免费PDF全文
996.
Ayami Yoshimi Marry M. van den Heuvel-Eibrink Irith Baumann Stephan Schwarz Ingrid Simonitsch-Klupp Pascale de Paepe Vit Campr Gitte Birk Kerndrup Maureen O’Sullivan Rita Devito Roos Leguit Miguel Hernandez Michael Dworzak Barbara de Moerloose Jan Stary Henrik Hasle Owen P. Smith Marco Zecca Albert Catala Markus Schmugge Franco Locatelli Monika Führer Alexandra Fischer Anne Guderle Peter N?llke Brigitte Strahm Charlotte M. Niemeyer 《Haematologica》2014,99(4):656-663
Refractory cytopenia of childhood is the most common subtype of myelodysplastic syndrome in children. In this study, we compared the outcome of immunosuppressive therapy using horse antithymocyte globulin (n=46) with that using rabbit antithymocyte globulin (n=49) in 95 patients with refractory cytopenia of childhood and hypocellular bone marrow. The response rate at 6 months was 74% for horse antithymocyte globulin and 53% for rabbit antithymocyte globulin (P=0.04). The inferior response in the rabbit antithymocyte globulin group resulted in lower 4-year transplantation-free (69% versus 46%; P=0.003) and failure-free (58% versus 48%; P=0.04) survival rates in this group compared with those in the horse antithymocyte globulin group. However, because of successful second-line hematopoietic stem cell transplantation, overall survival was comparable between groups (91% versus 85%; P=ns). The cumulative incidence of relapse (15% versus 9%; P=ns) and clonal evolution (12% versus 4%; P=ns) at 4 years was comparable between groups. Our results suggest that the outcome of immunosuppressive therapy with rabbit antithymocyte globulin is inferior to that of horse antithymocyte globulin. Although immunosuppressive therapy is an effective therapy in selected patients with refractory cytopenia of childhood, the long-term risk of relapse or clonal evolution remains. (ClinicalTrial.gov identifiers: ) NCT00662090相似文献
997.
Ursula Creutzig Martin Zimmermann Michael N. Dworzak Brenda Gibson Rienk Tamminga Jonas Abrahamsson Shau-Yin Ha Henrik Hasle Alexey Maschan Yves Bertrand Guy Leverger Christine von Neuhoff Bassem Razzouk Carmelo Rizzari Petr Smisek Owen P. Smith Batia Stark Dirk Reinhardt Gertjan L. Kaspers 《Haematologica》2014,99(9):1472-1478
The prognostic significance of early response to treatment has not been reported in relapsed pediatric acute myeloid leukemia. In order to identify an early and easily applicable prognostic factor allowing subsequent treatment modifications, we assessed leukemic blast counts in the bone marrow by morphology on days 15 and 28 after first reinduction in 338 patients of the international Relapsed-AML2001/01 trial. Both day 15 and day 28 status was classified as good (≤20% leukemic blasts) in 77% of patients. The correlation between day 15 and 28 blast percentages was significant, but not strong (Spearman correlation coefficient = 0.49, P<0.001). Survival probability decreased in a stepwise fashion along with rising blast counts at day 28. Patients with bone marrow blast counts at this time-point of ≤5%, 6–10%, 11–20% and >20% had 4-year probabilities of survival of 52%±3% versus 36%±10% versus 21%±9% versus 14%±4%, respectively, P<0.0001; this trend was not seen for day 15 results. Multivariate analysis showed that early treatment response at day 28 had the strongest prognostic significance, superseding even time to relapse (< or ≥12 months). In conclusion, an early response to treatment, measured on day 28, is a strong and independent prognostic factor potentially useful for treatment stratification in pediatric relapsed acute myeloid leukemia. This study was registered with ISRCTN code: 94206677. 相似文献
998.
999.
Stephen D. Smith Brian G. Till Mazyar S. Shadman Ryan C. Lynch Andrew J. Cowan Qian V. Wu Jenna Voutsinas Heather A. Rasmussen Katherine Blue Chaitra S. Ujjani Andrei Shustov Ryan D. Cassaday Jonathan R. Fromm Ajay K. Gopal 《British journal of haematology》2020,189(6):1119-1126
Tumor programmed death-ligand 1 (PD-L1) expression in diffuse large B-cell lymphoma (DLBCL) is associated with inferior outcomes. The first-line immunologically-replete setting may be an opportune time for PD-1 inhibition. We evaluated pembrolizumab in combination with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) in untreated patients with DLBCL. Eligible patients were age 18 or older, had adequate organ function, and had DLBCL requiring full-course therapy. Patients received pembrolizumab 200 mg/cycle with R-CHOP, primarily to assess toxicity. Response assessment utilized standard criteria, and PD-L1 staining was performed at a validated central laboratory. Among 30 patients, toxicity was comparable to standard R-CHOP but with two grade ≥3 immune related adverse events (rash, pneumonitis). The overall and complete response rate was 90% and 77%. With 25·5 months of median follow-up, 2-year progression-free survival (PFS) is 83%. PD-L1 expression was associated with non-GCB subtype, and improved PFS and survival. Pembrolizumab can safely be added to R-CHOP, and is associated with a high CR rate and 2-year PFS. Improved PFS with PR-CHOP in PD-L1 expressing tumors contradicts historical data in R-CHOP treated patients, supporting evaluation of PD-L1 as a biomarker to identify DLBCL patients who may benefit from this first-line strategy. 相似文献